Marco Milanesi

Marco Milanesi

Auto-generated profile, based on publicly available information

Marco Milanesi

“Cristina Gandini” Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2002 in Blood
Verified
Journal Article
Open access
PDF file
Massimo Di NicolaMassimo Di Nicola
Massimo Di Nicola
Carmelo Carlo-StellaCarmelo Carlo-Stella
Carmelo Carlo-Stella
MMMichele Magni
Michele Magni
MMMarco Milanesi
Marco Milanesi
PLPaolo D. Longoni
Paolo D. Longoni
AGAlessandro M. Gianni
Alessandro M. Gianni
CD2+ T lymphocytes obtained from either the donor of bone marrow stromal cells (BMSCs) or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic dendritic cells (DCs) or peripheral blood lymphocytes (PBLs). When autologous or allogeneic BMSCs were added back to T cells stimulated by DCs or PBLs, a significant and dose-dependent reduction of T-cell proliferation, ranging from 60% ± 5% to 98% ± 1%, was evident. Similarly, addition of BMSCs to T cells stimulated by polyclonal activators resulted in a 65% ± 5% (P = .0001) suppression of proliferation. BMSC- induced T-cell suppression was still evident when BMSCs were added in culture as late as 5 days after starting of MLRs. BMSC-inhibited T lymphocytes were not apoptotic and efficiently proliferated on restimulation. BMSCs significantly suppressed both CD4+ and CD8+ T cells (65% ± 5%, [P = .0005] and 75% ± 15% [P = .0005], respectively). Transwell experiments, in which cell-cell contact between BMSCs and effector cells was prevented, resulted in a significant inhibition of T-lymphocyte proliferation, suggesting that soluble factors were involved in this phenomenon. By using neutralizing monoclonal antibodies, transforming growth factor β1 and hepatocyte growth factor were identified as the mediators of BMSC effects. In conclusion, our data demonstrate that (1) autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, (2) this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and (3) T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.

7 May 2009 in Blood
Verified
Journal Article
Closed access
PDF file
ADAnna Dodero
Anna Dodero
CCCristiana Carniti
Cristiana Carniti
ARAnna Raganato
Anna Raganato
AVAntonio Vendramin
Antonio Vendramin
LFLucia Farina
Lucia Farina
PCPaolo Corradini
Paolo Corradini
Haploidentical hematopoietic stem cell transplantation provides an option for patients with advanced hematologic malignancies lacking a compatible donor. In this prospective phase 1/2 trial, we evaluated the role of reduced-intensity conditioning (RIC) followed by early add-backs of CD8-depleted donor lymphocyte infusions (DLIs). The RIC regimen consisted of thiotepa, fludarabine, cyclophosphamide, and 2 Gy total body irradiation. Twenty-eight patients with advanced lymphoproliferative diseases (n = 24) or acute myeloid leukemia (n = 4) were enrolled. Ex vivo and in vivo T-cell depletion was carried out by CD34+ cell selection and alemtuzumab treatment. The 2-year cumulative incidence of nonrelapse mortality was 26% and the 2-year overall survival (OS) was 44%, with a better outcome for patients with chemosensitive disease (OS, 75%). Overall, 54 CD8-depleted DLIs were administered to 23 patients (82%) at 3 different dose levels without loss of engraftment or acute toxicities. Overall, 6 of 23 patients (26%) developed grade II-IV graft-versus-host disease, mainly at dose level 2. In conclusion, our RIC regimen allowed a stable engraftment with a rather low nonrelapse mortality in poor-risk patients; OS is encouraging with some long-term remissions in lymphoid malignancies. CD8-depleted DLIs are feasible and promote the immune reconstitution.

1 May 2004 in Blood
Verified
Journal Article
Open access
PDF file
Carmelo Carlo-StellaCarmelo Carlo-Stella
Carmelo Carlo-Stella
Massimo Di NicolaMassimo Di Nicola
Massimo Di Nicola
RMRaffaella Milani
Raffaella Milani
AGAnna Guidetti
Anna Guidetti
MMMichele Magni
Michele Magni
AGAlessandro M. Gianni
Alessandro M. Gianni
The activity of recombinant human growth hormone (rhGH) in enhancing CD34+ cell mobilization elicited by chemotherapy plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) was evaluated in 16 hard-to-mobilize patients, that is, those achieving a peak of circulating CD34+ cells 10/μL or less, or a collection of CD34+ cells equal to or less than 2 × 106/kg. Patients who had failed a first mobilization attempt with chemotherapy plus rhG-CSF (5 μg/kg/d) were remobilized with chemotherapy plus rhG-CSF and rhGH (100 μg/kg/d). As compared with rhG-CSF, the combined rhGH/rhG-CSF treatment induced significantly higher (P ≤ .05) median peak values for CD34+ cells/μL (7 versus 29), colony-forming cells (CFCs)/mL (2154 versus 28 510), and long-term culture-initiating cells (LTC-ICs)/mL (25 versus 511). Following rhG-CSF and rhGH/rhG-CSF, the median yields of CD34+ cells per leukapheresis were 1.1 × 106/kg and 2.3 × 106/kg (P ≤ .008), respectively; the median total collections of CD34+ cells were 1.1 × 106/kg and 6 × 106/kg (P ≤ .008), respectively. No specific side effect could be ascribed to rhGH, except a transient hyperglycemia occurring in 2 patients. Reinfusion of rhGH/rhG-CSF-mobilized cells following myeloablative therapy resulted in prompt hematopoietic recovery. In conclusion, our data demonstrate that in poor mobilizers addition of rhGH to rhG-CSF allows the patients to efficiently mobilize and collect CD34+ cells with maintained functional properties. (Blood. 2004;103: 3287-3295)

1 February 2004 in Experimental Hematology
Verified
Journal Article
Closed access
Carmelo Carlo-StellaCarmelo Carlo-Stella
Carmelo Carlo-Stella
Massimo Di NicolaMassimo Di Nicola
Massimo Di Nicola
RMRaffaella Milani
Raffaella Milani
PLPaolo Longoni
Paolo Longoni
MMMarco Milanesi
Marco Milanesi
AGAlesssandro M Gianni
Alesssandro M Gianni

1 February 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Carmelo Carlo-StellaCarmelo Carlo-Stella
Carmelo Carlo-Stella
Massimo Di NicolaMassimo Di Nicola
Massimo Di Nicola
MTMaria Caterina Turco
Maria Caterina Turco
LCLoredana Cleris
Loredana Cleris
CLCristiana Lavazza
Cristiana Lavazza
AGAlessandro M. Gianni
Alessandro M. Gianni
The fully human anti-HLA-DR antibody 1D09C3 has been shown to delay lymphoma cell growth in severe combined immunodeficient (SCID) mice. The present study was aimed at (a) investigating the mechanism(s) of 1D09C3-induced cell death and (b) further exploring the therapeutic efficacy of 1D09C3 in nonobese diabetic (NOD)/SCID mice. The chronic lymphocytic leukemia cell line JVM-2 and the mantle cell lymphoma cell line GRANTA-519 were used. Generation of reactive oxygen species (ROS) and mitochondrial membrane depolarization were measured by flow cytometry following cell incubation with dihydroethidium and TMRE, respectively. Western blot analysis was used to detect c-Jun-NH2-kinase (JNK) phosphorylation and apoptosis-inducing factor (AIF). NOD/SCID mice were used to investigate the activity of 1D09C3 in early- or advanced-stage tumor xenografts. In vitro, 1D09C3-induced cell death involves a cascade of events, including ROS increase, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. Inhibition of JNK activity significantly reduced 1D09C3-induced apoptosis, indicating that 1D09C3 activity involves activation of the kinase. In vivo, 1D09C3 induces long-term disease-free survival in a significant proportion of tumor-bearing mice treated at an early stage of disease. Treatment of mice bearing advanced-stage lymphoma results in a highly significant prolongation of survival. These data show that 1D09C3 (a) exerts a potent antitumor effect by activating ROS-dependent, JNK-driven cell death, (b) cures the great majority of mice treated at an early-stage of disease, and (c) significantly prolongs survival of mice with advanced-stage disease. (Cancer Res 2006; 66(3): 1799-808)

1 August 2005 in Experimental Hematology
Verified
Journal Article
Closed access
ADAnna Dodero
Anna Dodero
MCMatteo Carrabba
Matteo Carrabba
RMRaffaella Milani
Raffaella Milani
ERElena Rizzo
Elena Rizzo
ARAnna Raganato
Anna Raganato
PCPaolo Corradini
Paolo Corradini